Evidence
Aust N Z J Psychiatry. 2023 Dec 21:48674231209840. doi: 10.1177/00048674231209840. Online ahead of print.
ABSTRACT
The advent of dopamine (D2) receptor-blocking medications over 70 years ago, ushered in a new era of biological treatment for schizophrenia. However, we argue that little subsequent progress has been made in translating this into fulfilled and fulfilling lives for people with schizophrenia. This Viewpoint asks why this is the case, and suggests ways forward for capitalising on extant and emerging new treatments for psychotic disorders, to the betterment of the lives of people living with schizophrenia.
PMID:38130026 | DOI:10.1177/00048674231209840
Add to Google Keep
Post to X
Share on Linkedin
Estimated reading time: 2 minute(s)
Latest: Psychiatryai.com #RAISR4D
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Seven decades of antipsychotic drugs: Why is the life of Australians with schizophrenia still so suboptimal?
🌐 90 Days
VR Related Evidence Matrix
Evidence Blueprint
Seven decades of antipsychotic drugs: Why is the life of Australians with schizophrenia still so suboptimal?
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Seven decades of antipsychotic drugs: Why is the life of Australians with schizophrenia still so suboptimal?
🌐 365 Days
VR Related Evidence Matrix
